People · Operator
Named in public records as an officer, director or promoter · active 2013–2024 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aura Biosciences, Inc. | — | Biotechnology | Series C | $198.2M | $2.5B | 2013 |
| X4 Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $73.2M | $1.2B | 2015 |
| Artax Biopharma, Inc. | — | Biotechnology | Series B | $48.0M | $75.7M | 2024 |
Alan Walts at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alan Walts on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter B. Finn | 2 | 11 |
| Casper Breum | 2 | 5 |
| Javier Garcia | 2 | 3 |
| Alan E. Walts | 2 | 3 |
| Casper E. Breum | 2 | 2 |
| David Johnson | 1 | 35 |
| Isaac Blech | 1 | 14 |
| Michael Gilman | 1 | 6 |
| Gino Santini | 1 | 5 |
| Raj Parekh | 1 | 5 |
| Michael Wyzga | 1 | 5 |
| Lawrence C. Best | 1 | 4 |
| Paula Ragan | 1 | 3 |
| Alison Lawton | 1 | 3 |
| Art Pappas | 1 | 3 |
| Gino W. Santini | 1 | 3 |
| Pedro Granadillo | 1 | 3 |
| Peter Wirth | 1 | 3 |
| Adam Mostafa | 1 | 3 |
| Edmundo Muniz, M.D., Ph.D. | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.